GB Patent

GB2527590A — Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer

Assigned to GW Pharma Ltd · Expires 2015-12-30 · 10y expired

What this patent protects

An active pharmaceutical ingredient (API) comprises or consists essentially of cannabidiol (CBD) and another cannabinoid (CB) selected from the group consisting of cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA) and tetrahydrocannabivarin (THCV) for use …

USPTO Abstract

An active pharmaceutical ingredient (API) comprises or consists essentially of cannabidiol (CBD) and another cannabinoid (CB) selected from the group consisting of cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA) and tetrahydrocannabivarin (THCV) for use as a medicament, preferably for use in the treatment of cancer, is provided. The cancer is preferably selected from one or more of: breast cancer, liver cancer, lung cancer, pancreatic cancer, melanoma, ovarian cancer, gastric cancer, renal cancer or bladder cancer. In particular, the API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiol (CBD) and tetrahydrocannabivarin (THCV).

Drugs covered by this patent

Patent Metadata

Patent number
GB2527590A
Jurisdiction
GB
Classification
—
Expires
2015-12-30
Drug substance claim
No
Drug product claim
No
Assignee
GW Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.